Elexacaftor/tezacaftor/ivacaftor in liver or kidney transplanted people with cystic fibrosis using tacrolimus, a drug-drug interaction study
The combination of cystic fibrosis transmembrane conductance regulator (CFTR) modulators elexacaftor, tezacaftor and ivacaftor (ETI) has shown a life changing clinical effect in people with cystic fibrosis (pwCF) with at least one phe508del mutation [1 –3]. The use of ETI in pwCF after solid organ transplant is controversial because of potential drug-drug interactions (DDI) with tacrolimus, a first-line immunosuppressive agent and a substrate of CYP3A4 [4]. The inhibition of CYP3A4 and the P-gp inhibition by ivacaftor has a potential risk to inc rease the systemic exposure to tacrolimus [5].
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Renske van der Meer, Erik B Wilms, Margot N Eggermont, Helena M Paalvast, Matthijs van Luin, Richard C J M van Rossen, Harry G M Heijerman Tags: Short Communication Source Type: research
More News: Cystic Fibrosis | Kidney Transplant | Kidney Transplantation | Liver | Liver Transplant | Prograf | Respiratory Medicine | Study | Tacrolimus | Transplant Surgery | Transplants | Urology & Nephrology